Genomic profiling of 175 lung cancer tumors revealed the high prevalence of TP53 alterations (43%) and relatively low co-occurrence of other cancer driver alterations, such as EGFR alterations (19%, Supplementary Fig. S2), which is much less than 40~60% in Asian lung cancer patients 20, 21. This evidence concerns the gene TP53 and cancer.